^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thrombopoietin receptor agonist

    Related drugs:
    16h
    A Clinical Study on the Efficacy and Safety of Hetrombopag in Preventing Thrombocytopenia Induced by Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (ChiCTR2600118519)
    P4, N=186, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New P4 trial
    18h
    Phase II Study of Romiplostim N01 for Cancer Treatment-Induced Thrombocytopenia in Hematologic Malignancies: A Prospective, Single-Arm Trial (ChiCTR2600117997)
    P=N/A, N=45, The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University
    New trial
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    6d
    BAPT: Baricitinib for Post-HSCT Persistent Thrombocytopenia (clinicaltrials.gov)
    P1/2, N=28, Not yet recruiting, Peking University People's Hospital
    New P1/2 trial
    8d
    PROMPT: Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (clinicaltrials.gov)
    P2, N=66, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Nplate (romiplostim)
    9d
    A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 (clinicaltrials.gov)
    P3, N=88, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Nplate (romiplostim) • Rui Lisheng (romiplostim biosimilar)
    9d
    Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma (clinicaltrials.gov)
    P2, N=11, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Nplate (romiplostim)
    17d
    HNCH-MBC10: A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=60, Completed, Henan Cancer Hospital | Recruiting --> Completed
    Trial completion
    17d
    CT-PLATE: Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. (clinicaltrials.gov)
    P2, N=136, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Dec 2028 | Initiation date: Jan 2026 --> Sep 2026 | Trial primary completion date: Apr 2028 --> Dec 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Nplate (romiplostim)
    18d
    Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. (PubMed, J Cell Physiol)
    Romiplostim-induced MF in a mouse model demonstrated extensive bone marrow (BM) CHI3L1 mRNA expression, which was reversed by clodronate treatment. A culture assay revealed that high CHI3L1 concentrations promoted extracellular matrix production by fibroblast cell lines, and that a CHI3L1-neutralizing antibody abrogated this effect. These results indicate the importance of CHI3L1 in the association between fibrocytes and fibroblasts in MF and could be a focus for future treatment.
    Journal
    |
    JAK2 (Janus kinase 2) • CD14 (CD14 Molecule) • CHI3L1 (Chitinase 3-like 1)
    |
    clodronate disodium • Nplate (romiplostim)
    21d
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    25d
    Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=174, Recruiting, Associazione Qol-one | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Promacta (eltrombopag)
    29d
    Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors (clinicaltrials.gov)
    P2, N=40, Recruiting, Changhai Hospital
    New P2 trial